CN1273463C - (1－苯甲酰甲基－3－苯基－3－哌啶基乙基)哌啶衍生物,制备它们的方法以及包含它们的药物组合物 - Google Patents

(1－苯甲酰甲基－3－苯基－3－哌啶基乙基)哌啶衍生物,制备它们的方法以及包含它们的药物组合物 Download PDF

Info

Publication number
CN1273463C
CN1273463C CNB008058261A CN00805826A CN1273463C CN 1273463 C CN1273463 C CN 1273463C CN B008058261 A CNB008058261 A CN B008058261A CN 00805826 A CN00805826 A CN 00805826A CN 1273463 C CN1273463 C CN 1273463C
Authority
CN
China
Prior art keywords
compound
formula
pharmaceutically acceptable
structural formula
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008058261A
Other languages
English (en)
Chinese (zh)
Other versions
CN1345317A (zh
Inventor
J·P·迪库
X·埃蒙兹-阿尔特
P·格莱
V·普罗伊托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9901593A external-priority patent/FR2789389B3/fr
Application filed by Sanofi Synthelabo SA, Sanofi Aventis France filed Critical Sanofi Synthelabo SA
Publication of CN1345317A publication Critical patent/CN1345317A/zh
Application granted granted Critical
Publication of CN1273463C publication Critical patent/CN1273463C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB008058261A 1999-02-10 2000-02-08 (1－苯甲酰甲基－3－苯基－3－哌啶基乙基)哌啶衍生物,制备它们的方法以及包含它们的药物组合物 Expired - Fee Related CN1273463C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9901593A FR2789389B3 (fr) 1999-02-10 1999-02-10 Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
FR99/04429 1999-04-07
FR99/01593 1999-04-07
FR9904429A FR2789390B3 (fr) 1999-02-10 1999-04-07 Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant

Publications (2)

Publication Number Publication Date
CN1345317A CN1345317A (zh) 2002-04-17
CN1273463C true CN1273463C (zh) 2006-09-06

Family

ID=26234812

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008058261A Expired - Fee Related CN1273463C (zh) 1999-02-10 2000-02-08 (1－苯甲酰甲基－3－苯基－3－哌啶基乙基)哌啶衍生物,制备它们的方法以及包含它们的药物组合物

Country Status (36)

Country Link
US (2) US6642233B1 (https=)
EP (1) EP1150970B1 (https=)
JP (1) JP4648544B2 (https=)
KR (1) KR100611261B1 (https=)
CN (1) CN1273463C (https=)
AR (1) AR028813A1 (https=)
AT (1) ATE370942T1 (https=)
AU (1) AU763716B2 (https=)
BG (1) BG65031B1 (https=)
BR (1) BR0008067A (https=)
CA (1) CA2360894C (https=)
CO (1) CO4980896A1 (https=)
CZ (1) CZ300765B6 (https=)
DE (1) DE60036081T2 (https=)
DK (1) DK1150970T3 (https=)
EE (1) EE04437B1 (https=)
ES (1) ES2291187T3 (https=)
FR (1) FR2789390B3 (https=)
HR (1) HRP20010566A2 (https=)
HU (1) HUP0201281A3 (https=)
ID (1) ID29219A (https=)
IL (2) IL144363A0 (https=)
ME (1) MEP11908A (https=)
NO (2) NO321149B1 (https=)
NZ (1) NZ513053A (https=)
PE (1) PE20001463A1 (https=)
PL (1) PL198561B1 (https=)
PT (1) PT1150970E (https=)
RS (1) RS50210B (https=)
RU (1) RU2220956C2 (https=)
SI (1) SI1150970T1 (https=)
SK (1) SK286401B6 (https=)
TR (1) TR200102331T2 (https=)
TW (1) TWI254712B (https=)
UA (1) UA70986C2 (https=)
WO (1) WO2000047572A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070745A2 (en) * 2002-02-20 2003-08-28 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids
US20050009798A1 (en) 2002-02-20 2005-01-13 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists
BRPI0507301A (pt) * 2004-01-30 2007-06-26 Pfizer Prod Inc composições farmacêuticas de antagonistas do receptor de nuerocinina e ciclodextrina e métodos para melhor toleráncia no local de injeção
FR2873373B1 (fr) * 2004-07-23 2006-09-08 Sanofi Synthelabo Derives de 4-arylmorpholin-3-one, leur preparation et leur application en therapeutique
GB2452696B (en) * 2007-08-02 2009-09-23 Cambridge Entpr Ltd 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions
DE102008015425A1 (de) * 2008-03-20 2010-01-21 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen zur Verringerung von Juckreiz und anderen dermatologischen Missempfindungen, die insbesondere bei Altershaut auftreten können, mit einem Gehalt an (1R,2S,5R)-2-Isopropyl-5-methyl-N-(2-(pyridin-2-yl)ethyl-cyclohexancarboxamid und/oder (1R,2S,5R)-N-(4-(Cyanomethyl)-phenyl)-2-isopropyl-5-methylcyclohexancarboxamid
DE102008015426A1 (de) * 2008-03-20 2009-09-24 Beiersdorf Ag Kühlende kosmetische oder dermatologische Zubereitungen mit einem Gehalt an (1R,2S,5R)-2-Isopropyl-5-methyl-N-(2-(pyridyn-2-yl)ethyl-cyclohexancarboxamid und/oder (1R,2S,5R)-N-(4-(Cyanomethyl)-phenyl)-2-isopropyl-5-methylcyclohexancarboxamid zu Reduktion von Hautrötungen
DE102008015428A1 (de) * 2008-03-20 2009-09-24 Beiersdorf Ag Kühlende Zubereitungen für den humanen Haut- und/oder Schleimhautkontakt mit einem Gehalt an (1R,2S,5R)-2-Isopropyl-5-methyl-N-(2-(pyridin-2-yl)ethyl-cyclohexancarboxamid und/oder (1R,2S,5R)-N-(4-(Cyanomethyl)-phenyl)-2-isopropyl-5-methylcyclohexancarboxamid

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US512901A (en) * 1894-01-16 Folding bed
GB821012A (en) * 1957-01-15 1959-09-30 Rhone Poulenc Sa New phenthiazine derivatives and processes for their preparation
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
CA2198084C (en) * 1994-08-25 2000-03-28 Timothy P. Burkholder Novel substituted piperidines useful for the treatment of allergic diseases
EP0714891A1 (en) 1994-11-22 1996-06-05 Eli Lilly And Company Heterocyclic tachykinin receptor antagonists

Also Published As

Publication number Publication date
EE04437B1 (et) 2005-02-15
NO321149B1 (no) 2006-03-27
US6951940B2 (en) 2005-10-04
RU2220956C2 (ru) 2004-01-10
BG105794A (en) 2002-05-31
NO20013878D0 (no) 2001-08-08
AU763716B2 (en) 2003-07-31
PT1150970E (pt) 2007-11-07
TWI254712B (en) 2006-05-11
ATE370942T1 (de) 2007-09-15
HRP20010566A2 (en) 2002-08-31
WO2000047572A1 (fr) 2000-08-17
JP4648544B2 (ja) 2011-03-09
HUP0201281A3 (en) 2003-05-28
PL198561B1 (pl) 2008-06-30
US6642233B1 (en) 2003-11-04
PE20001463A1 (es) 2001-02-21
ES2291187T3 (es) 2008-03-01
EP1150970B1 (fr) 2007-08-22
AR028813A1 (es) 2003-05-28
RS50210B (sr) 2009-07-15
FR2789390B3 (fr) 2001-03-09
NO20051958L (no) 2001-10-10
DK1150970T3 (da) 2007-12-17
TR200102331T2 (tr) 2002-03-21
IL144363A0 (en) 2002-05-23
IL180579A0 (en) 2007-06-03
ID29219A (id) 2001-08-16
HUP0201281A2 (en) 2002-09-28
DE60036081D1 (de) 2007-10-04
CA2360894A1 (en) 2000-08-17
AU2553100A (en) 2000-08-29
FR2789390A1 (fr) 2000-08-11
MEP11908A (en) 2010-06-10
CA2360894C (en) 2009-09-22
BG65031B1 (bg) 2006-12-29
BR0008067A (pt) 2001-11-06
UA70986C2 (uk) 2004-11-15
NO20013878L (no) 2001-10-10
KR100611261B1 (ko) 2006-08-10
CN1345317A (zh) 2002-04-17
HK1038927A1 (en) 2002-04-04
JP2002536442A (ja) 2002-10-29
SK286401B6 (sk) 2008-09-05
KR20010101818A (ko) 2001-11-14
US20040072840A1 (en) 2004-04-15
CZ20012888A3 (cs) 2001-11-14
EP1150970A1 (fr) 2001-11-07
EE200100417A (et) 2002-12-16
CZ300765B6 (cs) 2009-08-05
SK11392001A3 (sk) 2002-02-05
YU56401A (sh) 2004-03-12
NZ513053A (en) 2002-10-25
PL350243A1 (en) 2002-12-02
SI1150970T1 (sl) 2008-02-29
DE60036081T2 (de) 2008-05-15
CO4980896A1 (es) 2000-11-27

Similar Documents

Publication Publication Date Title
CN1056605C (zh) 作为人速激肽ⅲ受体的选择性拮抗剂的化合物及其用途
CN1293063C (zh) 取代的杂环化合物、其制备方法和含有这些化合物的药物组合物
CN1273451C (zh) 哌啶mch拮抗剂及其治疗肥胖症的用途
CN1298715C (zh) 作为组胺h3拮抗剂的非咪唑化合物
CN1231468C (zh) 化合物
CN1024547C (zh) 一类环胺化合物的制备方法
CN1249051C (zh) 毒蕈碱性激动剂
CN1163484C (zh) 4-芳酰基-哌啶-ccr-3受体拮抗剂ⅲ
CN1142161C (zh) 作为5－ht4受体拮抗剂的二氢苯并二噁烯羧酰胺与酮衍生物
CN1067655A (zh) 含氮杂环类化合物的氟代烷氧基苄氨基衍生物
CN1088917A (zh) 取代的苄氨基含氮非芳族杂环化合物
CN1150165C (zh) 用于治疗中枢神经系统紊乱的1-芳基磺酰基-2-芳基-吡咯烷衍生物
CN1688544A (zh) 作为蕈毒碱受体拮抗剂的含氟代和磺酰氨基的3,6－二取代的氮杂双环(3.1.0)己烷衍生物
CN1133593A (zh) 用于治疗的哌嗪化合物
CN1703403A (zh) 趋代谢的谷氨酸盐受体拮抗剂
CN1500081A (zh) 乙内酰硫脲及其在治疗糖尿病方面的用途
CN1087086A (zh) 噻唑基乙烯基苯基衍生物
CN1152030C (zh) 新的杂环化合物
CN1035178C (zh) 芳酰胺衍生物
CN1072219C (zh) 二氮杂䓬酮、其生产和用途
HK1044337A1 (en) Amide compounds
CN1642927A (zh) 环状酰胺
CN1918160A (zh) 用作趋化因子受体活性调节剂的新颖三环螺环衍生物
CN101048393A (zh) 作为γ－分泌酶抑制剂的取代的N－芳基磺酰基杂环胺
CN1922138A (zh) 芳氧基烷基氨基甲酸酯类衍生物,它们的制备方法与治疗用途

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060906

Termination date: 20120208